Literature DB >> 3694494

Kinetics of drug metabolism inhibition: use of metabolite concentration-time profiles.

P N Shaw1, J B Houston.   

Abstract

A simple model simulating the kinetics of drug metabolism inhibition interaction is investigated. The relative sensitivity of drug and metabolite concentration-time profiles as indices of inhibition is assessed. Under steady-state conditions where inhibitor concentrations are maintained constant, the determination of metabolite in addition to drug kinetics provides little additional information when inhibition is nonselective in nature. However metabolite profiles do offer increased sensitivity when parallel routes of metabolism exist and there is selectivity of inhibitory action. Non-steady-state conditions are also investigated as they often apply in inhibition studies; the inhibitor is often administered as a single dose or as a multiple dosing regimen rather than by a constant rate intravenous infusion. Under the former conditions, when inhibitor concentrations in the body fluctuate during the study, metabolite kinetics can be more useful than drug kinetics. The changes evident in the metabolite concentration-time profiles are substantial due to both the inhibition per se and the nonlinearity in the system arising from inhibitor elimination. It is concluded that metabolite kinetics provide a useful aid in the detection of drug metabolism inhibition interactions.

Mesh:

Substances:

Year:  1987        PMID: 3694494     DOI: 10.1007/bf01061759

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  12 in total

Review 1.  Drug interactions with cimetidine: an update.

Authors:  M C Gerber; G A Tejwani; N Gerber; J R Bianchine
Journal:  Pharmacol Ther       Date:  1985       Impact factor: 12.310

Review 2.  Drug metabolite kinetics.

Authors:  J B Houston
Journal:  Pharmacol Ther       Date:  1981       Impact factor: 12.310

Review 3.  Kinetics of drug--drug interactions.

Authors:  L Aarons
Journal:  Pharmacol Ther       Date:  1981       Impact factor: 12.310

Review 4.  Inhibitors of Cytochrome P-450s and their mechanism of action.

Authors:  B Testa; P Jenner
Journal:  Drug Metab Rev       Date:  1981       Impact factor: 4.518

Review 5.  Review of cimetidine drug interactions.

Authors:  E M Sorkin; D L Darvey
Journal:  Drug Intell Clin Pharm       Date:  1983-02

6.  Cimetidine interaction with liver microsomes in vitro and in vivo. Involvement of an activated complex with cytochrome P-450.

Authors:  J C Jensen; R Gugler
Journal:  Biochem Pharmacol       Date:  1985-06-15       Impact factor: 5.858

7.  Inhibition of antipyrine metabolite formation in rats in vivo.

Authors:  J C Rhodes; S T Hall; J B Houston
Journal:  Xenobiotica       Date:  1984-09       Impact factor: 1.908

8.  New heterocyclic modifiers of oxidative drug metabolism--I. 6-Substituted-2-aminobenzothiazoles.

Authors:  M Murray; E Lacey; G C Farrell
Journal:  Biochem Pharmacol       Date:  1986-06-15       Impact factor: 5.858

9.  The nature of microsomal monooxygenase inhibition by cimetidine.

Authors:  D J Winzor; B Ioannoni; P E Reilly
Journal:  Biochem Pharmacol       Date:  1986-07-01       Impact factor: 5.858

10.  Inhibition of antipyrine metabolite formation. Steady state studies with cimetidine and metyrapone in rats.

Authors:  P N Shaw; J Tseti; S Warburton; A Adedoyin; J B Houston
Journal:  Drug Metab Dispos       Date:  1986 Mar-Apr       Impact factor: 3.922

View more
  4 in total

1.  Physiological modeling of drug and metabolite: disposition of oxazepam and oxazepam glucuronides in the recirculating perfused mouse liver preparation.

Authors:  M V St-Pierre; D van den Berg; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

2.  Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition.

Authors:  G Barnett; J Segura; R de la Torre; M Carbó
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human.

Authors:  N Cazali; A Tran; J M Treluyer; E Rey; P d'Athis; J Vincent; G Pons
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

Review 4.  Factors affecting the clinical development of cytochrome p450 3A substrates.

Authors:  Megan A Gibbs; Natilie A Hosea
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.